TheraSphere multiple sphere images on blue background.

Unprecedented Predictability.

A proven tool for local tumor control

TheraSphere is the first and only FDA approved transarterial radiation therapy for hepatocellular carcinoma (HCC), delivering maximum damage to the tumor, sparing healthy tissue, and preserving treatment options.

TheraSphere vial and sphere image.

How TheraSphere works

TheraSphere is a treatment consisting of millions of tiny glass beads – each thinner than a strand of hair – containing radioactive Yttrium-90.

Administered by an Interventional Radiologist, each glass bead delivers a highly concentrated dose of radiation that targets the HCC liver tumor via the hepatic artery.

See how Therasphere works video image.





stay up to date sign-up

Stay up to date

Receive emails on relevant clinical data and news.

Offer more possibilities

In combination with other therapies, TheraSphere can offer patients more treatment possibilities and maintain quality of life.

See how TheraSphere gave Nicole treatment options that ultimately saved her life.

icon-clipboard icon-x-through-scapel icon-liver
Studied across all BCLC stages1 Minimally invasive outpatient procedure2 Maintains patient eligibility for future treatment

Key clinical data show how TheraSphere can improve survival outcomes

Every patient is unique and presents their HCC differently. TheraSphere is a versatile, evidence-based HCC therapy with proven clinical results of breakthrough outcomes.

12.5 years median os color bar with text.
TheraSphere + Liver Transplantation3

6.7 years median os color bar with text.

Local tumor control and prolonged time to progression4


TheraSphere treatment centers

Instantly locate treatment centers administering TheraSphere near you for your patients. 

Therasphere center finder map image.

Interested in learning more?

Have a field representative get in touch with you to learn more about the clinical benefits and possibilities that TheraSphere can offer your patients.

HCC: hepatocellular carcinoma; BCLC: Barcelona Clinic Liver Cancer staging system; Y-90: Yttrium-90; Gy: Gray; IQR: Interquartile Range; CR: Complete Response; PR: Partial Response.

* LEGACY. Hepatology. 2021


  1. Salem R et al. Hepatology 2018; 68(4): 1429-40
  2. Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable Hepatocellular Carcinoma: The LEGACY Study. Hepatology. 2021 Mar 19. doi: 10.1002/hep.31819.
  3. Gabr, A., Kulik, L., Mouli, S., Riaz, A., Ali, R., Desai, K., Mora, R.A., Ganger, D., Maddur, H., Flamm, S., Boike, J., Moore, C., Thornburg, B., Alasadi, A., Baker, T., Borja‐Cacho, D., Katariya, N., Ladner, D.P., Caicedo, J.C., Lewandowski, R.J. and Salem, R. (2020), Liver Transplantation Following Yttrium‐90 Radioembolization: 15‐year Experience in 207‐Patient Cohort. Hepatology. Accepted Author Manuscript. doi:10.1002/hep.31318 >=30% hepatic reserve.
  4. Lewandowski RJ, Gabr A, Abouchaleh N et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology. 2018; 287(3): 1050-1058.